Combined macitentan and dapagliflozin for heart failure with lung high blood pressure
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests whether adding two medications—macitentan and dapagliflozin—together is safe and effective for people with heart failure and a certain type of high blood pressure in the lungs. It might help improve your symptoms and daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older and live in South Korea.
- You have heart failure with a preserved or mildly reduced ejection fraction (over 40%).
- You have a specific type of high blood pressure in your lungs (confirmed by a heart catheter test).
- You are currently in WHO functional class II or III (meaning you have some symptoms with activity but not at rest).
- You are on stable heart failure medications for at least 3 months, unless you are not taking any.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three heart failure drugs (ARNI, SGLT2i, MRA) to see if they improve symptoms and outcomes in people with a type of heart failure where the heart pumps normally but doesn't relax properly (HFpEF).
This study tests a new combination of two medicines (balcinrenone and dapagliflozin) for people with heart failure and reduced kidney function. The goal is to see if this combination helps improve heart and kidney health better than current treatments.
This study tests an investigational drug (HS235) for people who have both heart failure with preserved ejection fraction and a type of pulmonary hypertension that can happen with it. The goal is to see if the drug can improve symptoms and quality of life.
This trial tests if combining baxdrostat with dapagliflozin helps protect kidney function and reduce heart risks in people with chronic kidney disease and high blood pressure. It's for adults who are already taking standard blood pressure medications.
This Phase 3 study continues treatment for people with pulmonary hypertension who finished an earlier parent study and have no other approved treatment option. It tests whether continuing their current medicine can help them keep getting benefit and stay safe.
This trial tests whether adding vericiguat to your usual heart failure medicines helps reduce pressure in your lungs and improve symptoms. You will have a CardioMEMS sensor already implanted to monitor your heart, and the study will use its readings to guide your care.
Hear when a new HFpEF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.